AKARI THERAPEUTICS PLC-ADR (AKTX) Forecast, Price Target & Analyst Ratings

NASDAQ:AKTX • US00972G2075

Current stock price

3.83 USD
-0.09 (-2.3%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AKARI THERAPEUTICS PLC-ADR (AKTX).

Forecast Snapshot

Consensus Price Target

Price Target
N/A
N/A
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 12, 2026
Period
Q1 / 2026
EPS Estimate
-$1.33
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
84.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
N/A
Upside
N/A
From current price of $3.83 to mean target of N/A, Based on 10 analyst forecasts
Low
N/A
Median
N/A
High
N/A

Price Target Revisions

1 Month
-8.62%
3 Months
-41.54%

Price Target Summary

The average price target has been revised downward by 41.54% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

AKTX Current Analyst RatingAKTX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5

Analyst Ratings History

AKTX Historical Analyst RatingsAKTX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8

Analyst Ratings Consensus

ChartMill Buy Consensus
84.00%
AKTX was analyzed by 10 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about AKTX.
In the previous month the buy percentage consensus was at a similar level.
AKTX was analyzed by 10 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-08Maxim GroupDowngrade Buy -> Hold
2026-04-01HC Wainwright & Co.Maintains Buy -> Buy
2026-01-05Ladenburg ThalmannInitiate Buy
2025-09-09HC Wainwright & Co.Reiterate Buy -> Buy
2025-07-18Maxim GroupInitiate Buy
2022-12-05HC Wainwright & Co.Initiate Buy
2022-11-01Alliance Global PartnersInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 12, 2026
Period
Q1 / 2026
EPS Estimate
-$1.33
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
N/A
Number of Analysts
6

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-3,900.00%
EPS (3 Months)
-2,400.00%

Next Earnings Summary

AKTX is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -1.33 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
AKTX revenue by date.AKTX revenue by date.
N/AN/AN/AN/AN/AN/A
748.98%		N/A
99.87%		N/A
42.21%
EBITDA
YoY % growth
AKTX ebitda by date.AKTX ebitda by date.
-30.58M-27.21M
11.02%		-35.04M
-28.78%		-23.45M
33.08%		-16.94M
27.76%		-17.97M
-6.08%		-17.21M
4.23%		-23.09M
-34.17%		-16.802M
27.23%		-16.633M
1.01%		N/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
AKTX ebit by date.AKTX ebit by date.
-30.59M-27.25M
10.92%		-35.08M
-28.73%		-23.49M
33.04%		-16.96M
27.80%		-17.98M
-6.01%		-17.21M
4.28%		-23.09M
-34.17%		-16.806M
27.22%		-16.647M
0.95%		-12.095M
27.34%		N/A
-22.97%		N/A
-34.58%		N/A
-62.41%		N/A
-9.85%		N/A
-2.71%		N/A
58.46%		N/A
256.18%		N/A
143.34%
Operating Margin
AKTX operating margin by date.AKTX operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
AKTX eps by date.AKTX eps by date.
N/A-1.80-60.00
-3,233.33%		N/A
66.00%		-18.60
8.82%		N/A
98.90%		N/A
91.28%		N/A
-1,376,654.15%		N/A
98.33%		N/A
15.00%		N/A
-100.00%		N/A
14.71%		N/A
-12.07%		N/A
15.90%		N/AN/AN/AN/AN/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-1.33-1.43-1.53-1.53
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/AN/AN/A
EBIT
Q2Q % growth		-3.379M
4.13%		-3.704M
-18.74%		-4.272M
-92.08%		-4.894M
-51.67%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

AKTX Yearly Revenue VS EstimatesAKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 2033 50M 100M 150M
AKTX Yearly EPS VS EstimatesAKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -50 -100 -150 -200

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-136.10%
EPS Next 5 Year
12.64%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

AKARI THERAPEUTICS PLC-ADR / AKTX Forecast FAQ

When does AKARI THERAPEUTICS PLC-ADR (AKTX) report earnings?

AKARI THERAPEUTICS PLC-ADR (AKTX) will report earnings on 2026-05-12.

What are the consensus estimates for AKARI THERAPEUTICS PLC-ADR (AKTX) next earnings?

The consensus EPS estimate for the next earnings of AKARI THERAPEUTICS PLC-ADR (AKTX) is -1.33 USD and the consensus revenue estimate is 0 USD.

Can you provide the consensus rating for AKARI THERAPEUTICS PLC-ADR stock?

The consensus rating for AKARI THERAPEUTICS PLC-ADR (AKTX) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.